FREMONT, Calif., June 4, 2012 /PRNewswire/ -- Velos, Inc. concluded its 2012 Velos Annual Meeting on May 18 at historic Haslett Warehouse in the iconic neighborhood of Fishermen’s Wharf in San Francisco, CA. At this year’s two-and-a-half-day conference, Velos unveiled the future of system interoperability in clinical research including an exciting new platformVelos eMaventhat empowers customers to leverage web-services and other advanced integration technologies to support interoperability among Velos and third-party applications.
“Velos eMaven provides an excellent platform for managing interoperability and information flow in the healthcare and clinical research arena,” said John McIlwain, CEO of Velos. “System administrators will find that establishing reliable connectivity between independent systems is easier than ever.”
Velos also revealed the latest advancements and capabilities of Velos eResearch v9.0. Product highlights included a new state-of-the-art user interface, streamlined navigation across the application, and full support of internationalization and localization.
Leading the digital research revolution on a separate front, Velos Aversian iPad app designed to manage patient adverse event and Graft-Versus-Host Disease historiesunderscored Velos’ continued endeavor to help customers increase clinical efficiency, reduce costs and provide better patient care.
“Mobile apps are an essential part of point-of-care data collection. Velos Aversi is Velos’ latest effort to provide research institutions with tools to increase efficiency and clinical data accuracy,” said McIlwain. Velos Aversi is now available for download at the Apple App Store for iPad.
Other highlights of the Velos 2012 Annual Meeting included:
- Velos announced its company and staff one year growth was in excess of 30%.
- Velos now employs over 100 full-time equivalents, making Velos the largest software company with a principal focus on operations at clinical research sites.
- Keynote speaker Dr. Lynn H. Vogel, PhD, the former CIO of MD Anderson Cancer Center, presented a compelling vision for collaboration and connectivity in Healthcare IT.
- Velos unveiled its subsystem to support the NCI’s Clinical Trial Reporting Program (CTRP).
- A leading academic medical center presented an advanced two-way interface between Velos and a leading EMR vendor.
- David Miklos, MD, Medical Director of the Stanford Cellular Therapeutic and Transplantation Laboratory conducted a dazzling real-time demonstration of Velos Aversi.
- The Velos Annual Meeting facilitated interaction among clinical research professionals from around the world, including Velos customers from as far as Australia and South Korea.
- One-on-one sessions provided functional and technical assistance, insight into best-practices for Velos products, and other guidance for Velos customers.
- Attendees raved about the exhilarating Velos-sponsored trolley tour of San Francisco. Several lucky attendees took home great prizes from a raffle, which included an iPod touch, a Kindle Fire and a wireless laser keyboard.
The next-generation of Velos products unveiled at the 2012 Velos Annual Meeting signal a new wave of technology that will continue to lead the way in helping clinical researchers reduce cost, improve efficiency and quality and ultimately provide better patient care.
About Velos Velos is the trusted clinical trial management resource for investigators, sponsors and academic leaders throughout the U.S. Velos eResearch is deployed for clinical research in all parts of the healthcare enterprise and supports a broad diversity of clinical departments and functional needs. System users are freed of redundant data entry and related time delays associated with most clinical research today. Velos integrates the clinical, administrative and financial information needs of research management, with an emphasis on flexibility and workflow. Founded in 1996, Velos, Inc. is privately held with headquarters in Fremont, California. For more information, visit http://www.velos.com/.
*This press release may contain forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements.
SOURCE Velos, Inc.
